An Evaluation of Infusion Therapy (Including Dextran) for Venous Thrombosis

Open Access
Publisher Website
Google Scholar
Abstract
Previous extensive research and clinical experience have shown that the dextrans are valuable therapies for thrombotic diseases. Disagreement upon the benefit derived from different molecular weights has been a feature of some of these reports. From the studies reported herein, we have concluded that direct perfusion of an injured vascular bed offers signifi- cantly better protection against venous clotting than systemic administration, regardless of the antithrombotic solution utilized. Indeed, none of the tested solutions offered protection superior to the control, dextrose/saline solution, when it was administered by direct perfusion. When the antithrombotic solutions are administered systemically, dex-tran (molecular weight, 40,000) and dextran (molecular weight, 75, 000) produce apparently equal protection against venous thrombotic occlusion and clot propagation, although they do not significantly alter the incidence of clot formation in the injured vein segments. No conclusions could be drawn regarding the effectiveness of hydroxyethyl starch as an antithrombotic agent.

This publication has 1 reference indexed in Scilit: